Zepp Health Corp
ZEPP NYSE· Electronic Computers
Last close · Oct 26, 2026
$2.54
KIRA · Stoqly’s AI analyst, in plain words
- Zepp Health Corp had $259M of revenue in fiscal 2025, up 41.8% on the year before. Over five years, revenue changed −23.5% a year on average.
- Its operating margin was −11.3%, up 14.6 pts: of every 100 in sales, about −11 is left after running the business.
- Zepp Health Corp lost $40.1M in fiscal 2025.
- Free cash flow was −$26.2M in fiscal 2025, −10.1% of revenue.
- Zepp Health Corp returned $1.2M to shareholders in fiscal 2025. The diluted share count fell 1.7%.
- Zepp Health Corp owes $2.4M more than it holds in cash.
Market cap
$40.4M
P/E
—
Revenue
$259M
Net income
−$40.1M
Free cash flow
−$26.2M
Operating margin
−11.3%
Zepp Health Corp in 30 seconds · fiscal 2025
Are sales growing?
+41.8%
Yes. Sales grew 41.8% last year.
Does it make a profit?
−15.5%
No. It lost money last year.
Does profit turn into cash?
−10.1%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Zepp Health Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 24, 2026
- Legal name
- Zepp Health Corp
- CIK
- 0001720446
Zepp Health Corp · ZEPP
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $981M | $614M | $353M | $183M | $259M |
| Revenue growth | −0.5% | −37.4% | −42.5% | −48.3% | 41.8% |
| Gross margin | 20.9% | 19.4% | 26.2% | 38.5% | 38.3% |
| Operating margin | 1.5% | −10.1% | −8.6% | −25.9% | −11.3% |
| Net income | $21.6M | −$43.2M | −$31.0M | −$75.7M | −$40.1M |
| Net margin | 2.2% | −7.0% | −8.8% | −41.5% | −15.5% |
| Diluted EPS | $1.28 | −$2.88 | −$2.08 | −$4.64 | −$2.56 |
| Cash | |||||
| Cash from operations | −$36.5M | −$117M | $42.6M | −$24.4M | −$25.7M |
| Capital expenditure | $7.2M | $1.2M | $1.6M | $1.4M | $0.5M |
| Free cash flow | −$43.7M | −$118M | $41.0M | −$25.8M | −$26.2M |
| FCF margin | −4.5% | −19.3% | 11.6% | −14.1% | −10.1% |
| Dividends paid | — | $6.3M | — | — | — |
| Share buybacks | $2.2M | $8.2M | $2.5M | $2.3M | $1.2M |
| Share count change | 1.5% | −6.8% | −1.3% | 6.5% | −1.7% |
| Debt and strength | |||||
| Cash and short-term investments | $233M | $134M | $139M | $92.1M | $57.0M |
| Debt incl. finance leases | $114M | $99.2M | $120M | $75.2M | $59.5M |
| Shareholders' equity | $458M | $387M | $351M | $252M | $215M |
| Net debt / EBITDA | −5.2x | — | — | — | — |
| Current ratio | 1.8x | 1.8x | 2.0x | 1.3x | 1.0x |
| Interest coverage | 2.1x | −7.5x | −4.5x | −8.5x | −5.1x |
| Returns and quality | |||||
| Return on capital | 3.9% | −13.8% | −7.2% | −15.9% | −10.6% |
| Return on equity | 4.9% | −10.2% | −8.4% | −25.1% | −17.2% |
| Return on tangible equity | 5.1% | −12.0% | −9.4% | −32.2% | −20.9% |
| Piotroski F-score | 3 | 1 | 6 | 3 | 5 |
| Altman Z'' | 3.7 | 2.7 | 3.2 | 1.2 | 0.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.1M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Zepp Health Corp · ZEPP
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.54 a share, the company is worth $40.4M.
Source: SEC EDGAR XBRL filings (CIK 0001720446). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.